Tumor Microenvironment Mechanism of LY007 Cell Injection for the Treatment of Relapsed and Refractory B-cell Non-Hodgkin's Lymphoma and the Exploration of Novel CAR-T Translational Research
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 入组人数
- 22
- 主要终点
- Level of M1 macrophage in peripheral blood collected before each cycle and at the point of progression if available for Mass Cytometry.
研究概览
简要总结
The T cell characteristics of 12 patients treated with CD20 CAR-T (LY007 cell injection) were analyzed to study their relationship with CAR-T anti-tumor activity, tumor killing, and in vivo proliferation, and to explore the mechanisms: before single harvesting, before bridging, before pretreatment, D0, D7, D14, D21, D28, and at the time of follow-up evaluation (plus time points if taking BTKi inhibitors: Peripheral blood specimens were collected before BTKi and 48h after BTKi discontinuation, and peripheral blood cells from patients before and after treatment were analyzed by mass spectrometry flow and single-cell sequencing.
Tumor tissue specimens were collected from patients at different time points (before pretreatment, during CAR-T expansion, and at PD) and subjected to single-cell sequencing.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Control
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •18-70 years of age (include 18 and 70);
- •Eastern Cooperative Oncology Group (ECOG) score of 0-1;
- •Cytologically or histologically confirmed diagnosis of CD20-positive B-NHL according to WHO 2016 criteria, including diffuse large B-cell lymphoma (including histologically transformed) and transformed follicular lymphoma (TFL);
- •Relapsed or refractory B-cell non-Hodgkin's lymphoma, subjects must have been treated with at least anthracyclines and rituximab (or other CD20-targeted agents) and have relapsed, failed to remit, or progressed after at least second-line therapy or autologous hematopoietic stem cell transplantation (auto-HSCT);
排除标准
- •Hepatitis B surface antigen (HBsAg) positive or Hepatitis B core antibody (HBcAb) positive with peripheral blood HBV DNA titer higher than the lower limit of detection; Hepatitis C virus (HCV) antibody positive with HCVRNA titer higher than the lower limit of detection; Human Immunodeficiency Virus (HIV) antibody positive; Positive syphilis serology.
- •Lymphoma involving only the central nervous system (CNS) (subjects with secondary CNS lymphoma are permitted to enroll); and
- •Lymphoma involving only the central nervous system (CNS) (subjects with secondary CNS lymphoma are eligible for enrollment).
- •prior CARB vaccination prior to enrollment;
- •Prior CAR-T therapy (except for prior targeted CD19 CAR-T therapy, including patients with stable disease evaluated at 3 months after CD19 CAR-T infusion or progressive disease evaluated at any time) or other genetically modified T-cell therapy prior to monotherapy.
结局指标
主要结局
Level of M1 macrophage in peripheral blood collected before each cycle and at the point of progression if available for Mass Cytometry.
时间窗: 2023.10-2025.12
Peripheral blood collected before each cycle and at the point of progression if available for Mass Cytometry to analyze the changes of immune celltypes and immune checkpoints.
Level of TIM-3 in peripheral blood collected before each cycle and at the point of progression if available for Mass Cytometry.
时间窗: 2023.10-2025.12
Peripheral blood collected before each cycle and at the point of progression if available for Mass Cytometry to analyze the changes of immune celltypes and immune checkpoints.
Expression levels of genes (known to be possible driver genes in lymphoma) analyzed from tumor tissues collected before treatment and at the point of progression if available for RNA sequencing after quality control.
时间窗: 2023.10-2025.12
Tumor tissues collected before treatment and at the point of progression if available for bulky RNA sequencing, single-cell RNA sequencing and spatial transcriptome sequencing after quality control. On the one hand, the difference of characteristics of tumor microenvironment will be analyzed in pre-treatment biopsy samples of patients grouped by efficacy; on the other hand, the changes of characteristics of tumor microenvironment will be analyzed between pre-treatment and post-treatment biopsy samples of patients.
Level of M2 macrophage in peripheral blood collected before each cycle and at the point of progression if available for Mass Cytometry.
时间窗: 2023.10-2025.12
Peripheral blood collected before each cycle and at the point of progression if available for Mass Cytometry to analyze the changes of immune celltypes and immune checkpoints.
Level of lymphocyte subpopulations in peripheral blood collected before each cycle and at the point of progression if available for Mass Cytometry.
时间窗: 2023.10-2025.12
Peripheral blood collected before each cycle and at the point of progression if available for Mass Cytometry to analyze the changes of immune celltypes and immune checkpoints.
Level of OX-40 in peripheral blood collected before each cycle and at the point of progression if available for Mass Cytometry.
时间窗: 2023.10-2025.12
Peripheral blood collected before each cycle and at the point of progression if available for Mass Cytometry to analyze the changes of immune celltypes and immune checkpoints.
Level of PD-1 in peripheral blood collected before each cycle and at the point of progression if available for Mass Cytometry.
时间窗: 2023.10-2025.12
Peripheral blood collected before each cycle and at the point of progression if available for Mass Cytometry to analyze the changes of immune celltypes and immune checkpoints.
Level of LAG-3 in peripheral blood collected before each cycle and at the point of progression if available for Mass Cytometry.
时间窗: 2023.10-2025.12
Peripheral blood collected before each cycle and at the point of progression if available for Mass Cytometry to analyze the changes of immune celltypes and immune checkpoints.
Expression levels of genes (known to be possible driver genes in lymphoma) analyzed from tumor tissues collected before treatment and at the point of progression if available for DNA sequencing after quality control.
时间窗: 2023.10-2025.12
Tumor tissues collected before treatment and at the point of progression if available for DNA sequencing after quality control. On the one hand, the difference of tumor mutations will be analyzed in pre-treatment biopsy samples of patients grouped by efficacy; on the other hand, the changes of tumor mutations will be analyzed between pre-treatment and post-treatment biopsy samples of patients.
次要结局
未报告次要终点
研究者
Zhao Weili
Principal Investigator, Clinical Professor
Ruijin Hospital